---
title: "A Personal Research Connection Leads Patient to ALS Trial | Sutter Health"
description: "After his own ALS diagnosis, scientist Vladimir Diaz-Ochoa enrolled in a CPMC clinical trial testing Relyvrio, hoping to slow the progression of his disease."
url: "https://vitals.sutterhealth.org/patient-stories/personal-connection-to-research-urges-patient-to-enroll-in-als-clinical-trial"
---

1.  [Home](https://vitals.sutterhealth.org/) /
2.  [Patient stories](https://vitals.sutterhealth.org/patient-stories) /
3.  Personal Connection To Research Urges Patient To Enroll In Als Clinical Trial

# Research Connection Leads Patient to Enroll in ALS Trial

After his own ALS diagnosis, scientist Vladimir Diaz-Ochoa enrolled in a CPMC clinical trial testing Relyvrio, hoping to slow the progression of his disease.

January 17, 2023 by Karin Fleming

![Research Connection Leads Patient to Enroll in ALS Trial](https://edge.sitecorecloud.io/sutterhealt962c-sutterhealt8fce-production57cc-4860/media/Project/SutterHealth/Vitals/patient-stories/GettyImages-460711949-3961d3d4.jpg?h=1500&iar=0&w=2000 "Research Connection Leads Patient to Enroll in ALS Trial")

When Vladimir Diaz-Ochoa, Ph.D., a scientist specializing in microbiology and immunology was diagnosed last year with a progressive neurodegenerative disease, the importance of medical research became even more personal.

Muscle spasms and weakness in his fingers prompted the 42-year-old Woodland, Calif., resident to seek medical care at Sutter Davis Hospital, where he was referred to specialists at Sutter’s California Pacific Medical Center (CPMC) in San Francisco.

![Middle-aged man in a pink shirt from waist up stands outside. He is smiling.](https://edge.sitecorecloud.io/sutterhealt962c-sutterhealt8fce-production57cc-4860/media/Project/SutterHealth/Vitals/patient-stories/Vlad-Diaz-bdb32b40.jpg "Vladimir Diaz-Ochoa, Ph.D., is enrolled in a Phase 3 clinical trial called Phoenix. The study is testing the effectiveness and safety of a new drug called Relyvrio™ for the treatment of ALS.")

[Dr. Jonathan Katz](https://www.sutterhealth.org/find-doctor/dr-jonathan-s-katz), a neurologist at CPMC’s [Forbes Norris MDA/ALS Research and Treatment Center](https://www.sutterhealth.org/services/neuroscience/forbes-norris-mda-als-center-cpni), performed an EMG (electromyography) and confirmed the diagnosis of ALS (amyotrophic lateral sclerosis)—a rare illness that affects motor neuron nerve cells in the brain and spinal cord. When the motor neurons die, the brain’s ability to start and control muscle movement is lost, causing symptoms such as muscle twitching and weakness in a limb or slurred speech. Eventually, ALS affects control of the muscles needed to move, speak, eat and breathe.

“I had begun searching for news of drugs or other therapies that might help slow the progression of my disease,” says Diaz-Ochoa. Dr. Katz, who is part of the Sutter Pacific Medical Foundation, counselled him that ALS remains an illness without a cure. With only two drugs (Rilutek® and Radicava®) approved by the United States Food and Drug Administration (FDA), Dr. Katz advised Diaz-Ochoa that an investigational drug being tested in a clinical trial might help slow the progression of his ALS.

“The most pressing challenge in treating ALS is finding a medication that addresses the biologic processes driving disease-related neurodegeneration,” says Dr. Katz. “Previously approved treatments have limited effectiveness in halting the persistent degeneration of motor nerves in the brain and spinal cord associated with ALS.”

Dr. Katz suggested Diaz-Ochoa consider enrolling in a Phase 3 clinical trial called [Phoenix](https://clinicaltrials.gov/ct2/show/NCT05021536). The study is testing the effectiveness and safety of a new drug called Relyvrio™.  Manufactured by Amylyx Pharmaceuticals Inc., Relyvrio works to help prevent motor neurons from dying. It was [approved by the FDA](https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-option-patients-als) in September 2022 based on data from a Phase 2 clinical trial called [Centaur](https://www.clinicaltrials.gov/ct2/show/NCT03127514) in which study participants took a placebo or Relyvrio for 24 weeks. Results showed a 25% slower decline in physical functioning for patients receiving the treatment.

“This new drug may allow patients to move, function and communicate more independently for longer, especially if taken early in the course of the disease,” says Dr. Katz. Research at CPMC contributed to the FDA’s approval of the drug.

![A portrait of Dr. Jonathan Katz. He is a Caucasian male wearing a grey suit with a blue shirt and red tie.](https://edge.sitecorecloud.io/sutterhealt962c-sutterhealt8fce-production57cc-4860/media/Project/SutterHealth/Vitals/patient-stories/Physician_WBR_SPMF_katz_jonathan-c1af6d47.jpg "Dr. Jonathan Katz studies amyotrophic lateral sclerosis (ALS) at the Forbes Norris MDA/ALS Research and Treatment Center at Sutter’s California Pacific Medical Center in San Francisco.")

Diaz-Ochoa made a quick decision: the travel to San Francisco would be worth the opportunity to participate in the clinical trial of a drug that might slow the progression of his illness and ease his symptoms. A father of two children, aged 8 and 5 years, the possibility of life-extending treatment was also top of mind for the scientist.

“I truly appreciate healthcare sites like Sutter’s Forbes Norris MDA/ALS Research and Treatment Center that are bringing research and clinical trials to the forefront of medical care and which provide new hope for cure,” says Diaz-Ochoa. “I was honored to join the clinical trial and contribute to the cutting-edge science that helped usher in a novel treatment for ALS.”

Diaz-Ochoa is now being treated with Relyvrio™. As part of his participation in the Phoenix clinical trial, he will be monitored by his doctors closely over the next several months to help determine an ongoing, effective and safe treatment plan.

Find this and more [clinical trials](https://www.sutterhealth.org/research/clinical-trials) at Sutter Health.

## Amyotrophic lateral sclerosis (ALS)

Changes in the brain, spine or nerves affect everyday life. Our amyotrophic lateral sclerosis (ALS) services offer evaluation, treatment and support to help you understand symptoms and explore care options.

[Learn more about Amyotrophic lateral sclerosis (ALS)](https://www.sutterhealth.org/services/amyotrophic-lateral-sclerosis-als)

## Related articles

### [Sutter Health Breaks Ground on Advanced Neuroscience Complex](https://vitals.sutterhealth.org/research-innovation/sutter-health-breaks-ground-on-442-million-neuroscience-complex-in-san-francisco)

### [Sutter's Neuroscience Program Receives National Recognition](https://vitals.sutterhealth.org/our-people/sutters-neuroscience-program-receives-national-recognition)

### [Fighting ALS: New Therapy Has Potential to Change Lives](https://vitals.sutterhealth.org/research-innovation/fighting-als-new-investigational-therapy-holds-the-potential-to-change-lives)

### [ALS Clinical Trial Leads to U.S. FDA Approval of New Therapy](https://vitals.sutterhealth.org/patient-stories/als-clinical-trial-als-clinical-trial-leads-to-u-s-fda-approval-of-new-therapy)

[See all from Patient stories](https://vitals.sutterhealth.org/patient-stories)

## Check your Vitals

Get the latest in health innovation, community impact and patient care from Sutter Health — delivered straight to your inbox.

[Subscribe to Vitals](https://vitals.sutterhealth.org/subscribe)

```json
{"@context":"https://schema.org","@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org","logo":"https://www.sutterhealth.org/static/images/sutter-health-logo.svg","address":{"@type":"PostalAddress","streetAddress":"2200 River Plaza Drive","addressLocality":"Sacramento","addressRegion":"CA","postalCode":"95833","addressCountry":"US"},"areaServed":{"@type":"AdministrativeArea","name":"California"},"sameAs":["https://www.facebook.com/SutterHealth","https://www.instagram.com/sutterhealth/","https://x.com/SutterHealth","https://www.youtube.com/sutterhealth","https://www.linkedin.com/company/sutter-health","https://en.wikipedia.org/wiki/Sutter_Health"]}
```

```json
{"@context":"https://schema.org","@type":"WebPage","name":"A Personal Research Connection Leads Patient to ALS Trial","description":"After his own ALS diagnosis, scientist Vladimir Diaz-Ochoa enrolled in a CPMC clinical trial testing Relyvrio, hoping to slow the progression of his disease.","url":"https://vitals.sutterhealth.org/patient-stories/personal-connection-to-research-urges-patient-to-enroll-in-als-clinical-trial","breadcrumb":{"@id":"https://vitals.sutterhealth.org/patient-stories/personal-connection-to-research-urges-patient-to-enroll-in-als-clinical-trial#breadcrumblist"}}
```

```json
{"@context":"https://schema.org","@type":"Article","@id":"https://vitals.sutterhealth.org/patient-stories/personal-connection-to-research-urges-patient-to-enroll-in-als-clinical-trial#article","url":"https://vitals.sutterhealth.org/patient-stories/personal-connection-to-research-urges-patient-to-enroll-in-als-clinical-trial","headline":"A Personal Research Connection Leads Patient to ALS Trial","description":"After his own ALS diagnosis, scientist Vladimir Diaz-Ochoa enrolled in a CPMC clinical trial testing Relyvrio, hoping to slow the progression of his disease.","articleSection":"Patient stories","inLanguage":"en-US","datePublished":"2023-01-17T07:57:33-08:00","dateModified":"2026-11-04T13:28:11-08:00","author":[{"@context":"https://schema.org","@type":"Person","name":"Karin Fleming"}],"publisher":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"},"abstract":"After his own ALS diagnosis, scientist Vladimir Diaz-Ochoa enrolled in a CPMC clinical trial testing Relyvrio, hoping to slow the progression of his disease.","image":{"@type":"ImageObject","url":"https://edge.sitecorecloud.io/sutterhealt962c-sutterhealt8fce-production57cc-4860/media/Project/SutterHealth/Vitals/patient-stories/GettyImages-460711949-3961d3d4.jpg?h=1500&iar=0&w=2000","width":"2000","height":"1500","caption":"Research Connection Leads Patient to Enroll in ALS Trial"},"thumbnailUrl":"https://edge.sitecorecloud.io/sutterhealt962c-sutterhealt8fce-production57cc-4860/media/Project/SutterHealth/Vitals/patient-stories/GettyImages-460711949-3961d3d4.jpg?h=1500&iar=0&w=2000","isPartOf":{"@type":"WebSite","@id":"https://vitals.sutterhealth.org/#website","name":"Vitals - Sutter Health","url":"https://vitals.sutterhealth.org"},"mainEntityOfPage":"https://vitals.sutterhealth.org/patient-stories/personal-connection-to-research-urges-patient-to-enroll-in-als-clinical-trial","about":[{"@type":"Thing","name":"Amyotrophic lateral sclerosis (ALS)"}],"mentions":[{"@type":"Hospital","@id":"https://www.sutterhealth.org/find-location/facility/cpmc-van-ness-campus-1043247265#hospital","name":"CPMC Van Ness Campus","url":"https://www.sutterhealth.org/find-location/facility/cpmc-van-ness-campus-1043247265"}]}
```

```json
{"@context":"https://schema.org","@type":"BreadcrumbList","@id":"https://vitals.sutterhealth.org/patient-stories/personal-connection-to-research-urges-patient-to-enroll-in-als-clinical-trial#breadcrumblist","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://vitals.sutterhealth.org/"},{"@type":"ListItem","position":2,"name":"Patient stories","item":"https://vitals.sutterhealth.org/patient-stories"},{"@type":"ListItem","position":3,"name":"Personal Connection To Research Urges Patient To Enroll In Als Clinical Trial"}]}
```